QPS, a CRO, has expanded its global footprint with new clinics in the Netherlands and India. QPS Netherlands recently opened a second clinic, positioned on the grounds of the Medical Center Leeuwarden (MCL), in the Netherlands. While initial studies will focus on neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease, the clinic will ultimately be open to studies in a wide variety of disease states.

According to Izaak den Daas, Ph.D., Director of Patient Studies at QPS Netherlands, “From 2017 onwards, discussion between QPS and medical staff and management of MCL resulted in the mutual agreement of the establishment of a dedicated clinical pharmacology patient unit on the premises of MCL in close vicinity of the policlinic stations of the medical specialists.”
 
It features adaptable function rooms and eight bedrooms for overnight stays, the facility was specifically designed to address the safety and security needs of elderly patients with Alzheimer’s and Parkinson’s disease. The first patient study will start on September 15, 2019.

In addition, QPS India opened a new early-phase clinical facility in Hyderabad, India, with a 138-bed capacity spread over four clinical units. The facility is ready for Phase I healthy volunteers as well as Phase II/III patient populations. It also includes a dedicated area for women and is easily accessible, ensuring the health and safety of all volunteers.  
 
QPS India has successfully cleared over 22 regulatory inspections from the U.S. FDA, Medicines and Healthcare Products Regulatory Agency (MHRA), European Medicines Agency (EMA), World Health Organization (WHO), and Drug Controller General of India (DCGI). In addition, QPS India is a partner to several prominent generic pharmaceutical companies and has contributed to first-to-file and 505(b)(2) projects.
 
“QPS India is well known for quality, compliance, and commitment with a good regulatory track,” says Daniel Rapaka, Deputy General Manager of Business Development at QPS India. “It’s a one-stop solution for all generic bioavailability and bioequivalence (BA/BE) studies and clinical trials.”